MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients

Inclusion Criteria:

1. Patient must have undergone autologous stem cell transplantation, with melphalan as a preparative regimen, within 12 months of initiation of induction therapy for newly diagnosed myeloma.
2. Time to initiation of maintenance therapy. Patients may start maintenance therapy as early as 60 days post-transplant and up to 180 days post-transplant; as long as they meet the following criteria: * Platelet count >/= 100,000/mm^3 * Neutrophil count >/= 1000/mm^4 * Total bilirubin </= 1.5 x ULN * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) </= 3 x ULN * Creatinine < 2.5 mg/dL * Recovered (ie, < Grade 1 toxicity) from the reversible effects of autologous stem cell transplant
3. Patients whose primary therapy was changed due to suboptimal response of toxicity will be eligible, however no more than 2 regimens will be allowed prior to ASCT.
4. Male or female patients 18 years or older.
5. Patients must have an Eastern Cooperative Oncology Group (ECOG) status of 0 to 2.
6. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
7. Female patients who: Are postmenopausal for at least 1 year before the Screening visit, OR Are surgically sterile, OR IF they are childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse. Male patients, even if surgically sterilized (ie, status post vasectomy), who: Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study treatment, OR Agree to completely abstain from heterosexual intercourse.

Exclusion Criteria:

1. Patient has >/= Grade 2 peripheral neuropathy.
2. Major surgery within 14 days before the first dose of study drug.
3. Radiotherapy within 14 days before enrollment
4. Known active central nervous system involvement
5. Systemic treatment, within 14 days before study enrollment, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
6. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or GI procedure that could interfere with the oral absorption or tolerance of treatment.
7. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
8. Female subject is pregnant or lactating.
9. Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation or completion of treatment according to this protocol.
10. QTc > 470 milliseconds (msec) on a 12-lead ECG obtained during the Screening period. If a machine reading is above this value, the ECG should be reviewed by a qualified reader and confirmed on a subsequent ECG.
11. Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis.
12. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
13. Known allergy to any of the study medications, their analogues, or excipients in the various formulations.
14. Participation in clinical trials with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial.
15. Failure to have fully recovered (ie, </= Grade 1 toxicity) from the effects of prior chemotherapy regardless of the interval since last treatment.
16. Co-morbid systemic illnesses or other severe concurrent disease that, in the judgement of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.